Considering that STAT3 activation in KRAS mutant pancreatic cancer was reported to facilitate cell progression47, the KRAS L19F mutation in our patient (patient number 10) may have interaction potential with STAT3 mutation. This evidence concerns the gene STAT3 and familial pancreatic carcinoma.